AZD 1208

Drug Profile

AZD 1208

Alternative Names: AZD1208

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene proteins c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer
  • Discontinued Acute myeloid leukaemia; Lymphoma; Solid tumours

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Prostate cancer in USA, before April 2017
  • 01 Apr 2017 Adverse events and pharmacodynamics data from a preclinical trial in Prostate cancer presented at the 108th annual meeting of the American Association for Cancer Research (AACR-2017)
  • 30 Sep 2014 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in USA and Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top